GleamWall
中文EN

RYTM RHYTHM PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1649904 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY61.0%
TTM net income YoY-0.8%
TTM EPS YoY6.1%
Revenue 3-yr CAGR65.5%
Net income 3-yr CAGR—

Margins

Gross margin88.2%
Operating margin-66.7%
Net margin-69.0%
FCF margin—
EBITDA margin—

Returns

ROE-163.7%
ROA-40.8%
ROIC (approx.)-83.0%
Asset turnover0.59x

Leverage & solvency

Liabilities / assets54.5%
Debt / equity1.17x
Current ratio2.78x
Interest coverage-10.27x

Cash quality & payout

Operating cash flow / net income0.42x
Accruals ratio-23.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$189.76M$130.13M
Cost of revenue$19.49M$13.37M
Gross profit$170.26M$116.76M
R&D expense$167.34M$237.96M
SG&A expense$194.94M$144.30M
Operating income-$192.02M-$265.50M
Interest expense$20.58M$20.60M
Pretax income-$196.04M-$260.26M
Income tax$497,000$346,000
Net income-$196.54M-$260.60M
EBITDA-$191.52M-$264.80M
EPS (basic)-3.11-4.34
EPS (diluted)-3.11-4.34
Weighted avg. shares (diluted)64.98M61.00M
Balance sheet
Cash & equivalents$54.30M$89.14M
Short-term investments$334.65M$231.43M
Receivables$26.08M$18.51M
Inventory$25.75M$18.74M
Current assets$466.92M$374.20M
PP&E, net$1.10M$632,000
Intangibles$5.32M$6.17M
Total assets$480.20M$392.27M
Current liabilities$105.94M$115.52M
Short-term debt$7.30M$1.54M
Long-term debt$100.89M$108.27M
Total debt$108.18M$109.81M
Total liabilities$210.17M$227.72M
Shareholders' equity$139.07M$21.73M
Net debt$53.88M$20.67M
Shares outstanding67.21M62.39M
Cash flow statement
Operating cash flow-$115.67M-$113.88M
Capital expenditure$953,000$0
Free cash flow-$116.63M-$113.88M
Investing cash flow-$137.15M-$48.17M
Financing cash flow$217.96M$191.24M
Depreciation & amortization$500,000$700,000
Stock-based compensation$66.82M$39.68M

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.